BRIEF COMMUNICATION

Low-Dose Difluoromethylornithine and Polyamine Levels in Human Prostate Tissue

Edward M. Messing, Richard R. Love, Kendra D. Tutsch, Ajit K. Verma, Jeffrey Douglas, Marcia Pomplun, Ruby Simsiman, George Wilding

Affiliations of authors: E. M. Messing, Department of Urology, University of Rochester Medical Center, NY; R. R. Love, K. D. Tutsch, M. Pomplun, G. Wilding (Section of Medical Oncology, Department of Medicine), A. K. Verma, R. Simsiman (Department of Human Oncology), J. Douglas (Department of Biostatistics and Informatics), University of Wisconsin School of Medicine, Madison.

Correspondence to: Richard R. Love, M.D., 1300 University Ave., 7C MSC, Madison, WI 53706.

Difluoromethylornithine is a noncompetitive inhibitor of ornithine decarboxylase, which catalyzes the rate-limiting step in polyamine synthesis. Induction of ornithine decarboxylase activity has been closely associated with the action of tumor promoters (1,2), growth factors (3,4), and mitogenic hormones (5-7). Difluoromethylornithine inhibits the development of spontaneous and carcinogen-induced mammalian tumors in vivo, including carcinomas of the breast, colon, epidermis, and bladder (8-11). At low difluoromethylornithine doses of 0.5 g/m2 or less given by mouth daily, polyamine suppression has been demonstrated in skin and colonic tissues (12-14), with limited and reversible toxicity (13,14). The prostate gland is of particular interest with respect to difluoromethylornithine because adult mammalian prostatic tissue has been reported to have high activities of ornithine decarboxylase (5) and elevated concentrations of polyamines (15). These become even more elevated in mammalian prostatic carcinoma (15,16). We studied the effects of 2 weeks of oral, daily, low-dose (0.5 g/m2) difluoromethylornithine on human peripheral zone prostatic ornithine decarboxylase activities and polyamine levels in patients undergoing open prostatic surgery.

Under an institutionally approved protocol and after written informed consent, men undergoing radical prostatectomy with biopsy-proven diagnoses of prostatic cancer (n = 24) or cystoprostatectomy for bladder cancer without prostatic cancer (n = 1), whose serum creatinine levels were 1.5 mg/100 mL or less and who had no important major organ system or hearing deficits, were randomly assigned in a 3 : 2 ratio to receive oral difluoromethylornithine given at 0.5 g/m2 once daily (n = 15) or no treatment (n = 10) for 2 weeks. One difluoromethylornithine-treated case patient was not evaluable. Plasma testosterone, serum prostate-specific antigen (PSA), and prostatic acid phosphatase levels were measured and volar forearm punch skin biopsies were performed as previously described (17) before the drug was started and 12-14 hours after the final dose was given. At surgery, 12-14 hours after the last ingested dose of difluoromethylornithine, after the prostate gland was removed the prostate gland was immediately sampled using a True-cut biopsy needle ex vivo. Tissues that contained suspicious prostatic nodules were sampled with a minimum of one core taken from the peripheral zone from each side of the prostate (12 patients). In 12 patients, three similar cores were taken from each side of the prostate. Each core, roughly 2.0 mm in diameter and 18 mm long, was divided longitudinally into thirds. The middle section was placed in 10% formalin for subsequent histologic inspection, and the end sections were analyzed for ornithine decarboxylase activities and polyamine concentrations.

Tissue specimens were homogenized in ice-cold buffer (50 nM Tris-HCl [pH 7.5], 0.1 mM EDTA, and 0.1 mM pyridoxal phosphate). Ornithine decarboxylase activity in the clear supernatant and tissue polyamines were measured by previously reported methods (12,13). Plasma testosterone, serum PSA, and serum prostatic acid phosphatase levels were measured by standard laboratory techniques.

The primary analysis concerned examining differences in ornithine decarboxylase activity and polyamine levels in prostate tissue between the difluoromethylornithine-treated and control groups. The values assigned to each subject were the average of the samples or the geometric mean when logarithmic transformations were used. Differences in the mean ornithine decarboxylase activity in prostate tissue were examined by a two-sample t test. Because the variance of polyamine measurements appeared to increase directly with their concentrations, polyamine levels were compared after logarithmic (base 10) transformations were taken. The log-transformed data were then analyzed with two-sample t tests.

The difluoromethylornithine-treated subjects (n = 14) completed 2 weeks of treatment without any reported toxic effects. Comparisons of pretreatment groups and post-treatment groups with respect to pretreatment clinical stage and post-treatment pathologic stage, tumor grades (Gleason scores), and levels of PSA, prostatic acid phosphatase, and testosterone showed no evidence of a treatment effect. Mean putrescine concentrations in prostate tissue were statistically significantly lower in the difluoromethylornithine-treated group (log [nmol/mg DNA]: difluoromethylornithine-treated group = 1.43; control group = 1.95; two-sided P = .03). Prostatic ornithine decarboxylase, spermidine, and spermine concentrations were comparable in the two groups. Skin ornithine decarboxylase levels tended to be lower after treatment in the difluoromethylornithine-treated group (not statistically significant). Although the numbers of prostatic tissue cores ranged from two to six in individual subjects and a majority of tissue cores did not show cancer despite specific attempts to sample palpable cancer nodules, no associations of difluoromethylornithine treatment with these parameters were observed.

Both the polyamine biosynthetic and the interconversion pathways regulate polyamine levels (18,19). Difluoromethylornithine inhibits ornithine decarboxylase activity and reduces putrescine and occasionally spermidine levels. Thus, it may not be surprising that only putrescine levels were found to be depressed in this study. It is uncertain whether a longer duration of administration of difluoromethylornithine would have depleted the other polyamines from prostatic tissue.

The lack of a substantial effect of difluoromethylornithine on prostatic ornithine decarboxylase activities or concentrations of other polyamines might be attributable to surgical biopsy trauma aftereffects. In specimens of urothelium taken at the beginning and the end of open surgical procedures, "post-trauma" tissue had roughly half the ornithine decarboxylase activity of "pretrauma" specimens (Messing EM: unpublished data). The putrescine-reducing effect of difluoromethylornithine did not appear to be due to any influence on the hypothalamic-pituitary-testicular axis because no changes in plasma testosterone or androgen-response gene products—serum PSA and serum prostatic acid phosphatase—were detected. Because of the very slow cellular proliferation rate of the aging prostate and in most cases of localized prostate cancer, it is not surprising that just 2 weeks of treatment with difluoromethylornithine had no distinguishable histologic effects.

Unfortunately, in this study, despite attempts to sample prostatic carcinoma, this did not regularly occur. Thus, it is unknown whether there is a differential biologic effect of difluoromethylornithine in malignant and normal (or benignly hyperplastic) prostatic tissues on putrescine concentrations or ornithine decarboxylase activity levels.

It is unknown whether prostatic carcinoma, by perhaps lacking interconversion enzymes, might be particularly susceptible to a difluoromethylornithine blockade of polyamine synthesis or whether combining polyamine synthesis inhibitors with other agents that can interfere with polyamine salvage pathways might provide increased therapeutic effects in prostatic tissue. In addition, because difluoromethylornithine has direct effects on prostatic tissue without affecting androgen levels, combining difluoromethylornithine with antiandrogenic treatments may have synergistic, or at least additive, prostatic cancer preventive capabilities. Similarly, combining difluoromethylornithine with prostaglandin synthesis inhibitors (20) or differentiating agents may also have additive benefits.

Although long-term daily doses of difluoromethylornithine of 0.5 g/m2 appear to be associated with the development of reversible ototoxicity (13) and lower doses may have similar biochemical and no toxic effects (14), a schedule of intermittent treatment may also avert this toxicity. Further studies of difluoromethylornithine in populations at risk for prostate cancer seem to be warranted.

NOTES

Editor's note: R. R. Love has applied for a grant in support of further study of difluoromethylornithine. If further study is pursued, partial support will be provided by ILEX Oncology, Inc. (San Antonio, TX). ILEX holds the patent for difluoromethylornithine.

Supported by Public Health Service grant U01CA59352 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

REFERENCES

1 Boutwell RK. Some biological aspects of skin carcinogenesis. Prog Exp Tumor Res 1964;4:207-50.

2 Boutwell RK, Verma AK, Ashendel CL, Astrup E. Mouse skin: a useful model system for studying the mechanism of chemical carcinogenesis. In: Hecker E, Fusenig NE, Kunz W, Marks F, Theilmann H, editors. Carcinogenesis—a comprehensive survey. New York (NY): Raven Press; 1982. p. 1-12.

3 Messing EM, Reznikoff CA. Normal and malignant urothelium: in vitro effects of epidermal growth factor. Cancer Res 1987;47:2230-5.[Abstract]

4 Messing EM, Hanson P, Reznikoff CA. Normal and malignant human urothelium: in vitro response to blockade of polyamine synthesis and interconversion. Cancer Res 1988;48:357-61.[Abstract]

5 Fjosne HE, Strand H, Ostensen MA, Sunde A. Ornithine decarboxylase and S-adenosylmethionine decarboxylase activity in the accessory sex organs of intact, castrated, and androgen-stimulated castrated rats. Prostate 1988;12:309-20.[Medline]

6 Fjosne HE, Ostensen MA, Haarstad H, Sunde A. Androgen regulation of polyamine synthesis in seminal vesicle and in different lobes of the rat prostate. Prostate 1990;17:1-11.[Medline]

7 Rui H, Purvis K. Prolactin selectively stimulates ornithine decarboxylase in the lateral lobe of the rat prostate. Mol Cell Endocrinol 1987;50:89-97.[Medline]

8 Fozard JR, Prakash NJ. Effects of DL-{alpha}-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, on the rat mammary tumor induced by 7,12-dimethylbenz[a]anthracene. Naunyn Schmiedebergs Arch Pharmacol 1982;320:72-7.[Medline]

9 Tutton PJ, Barkla DH. Comparison of the effects of an ornithine decarboxylase inhibitor on the intestinal epithelium and on intestinal tumors. Cancer Res 1986;46(12 Pt 1):6091-4.[Abstract]

10 Takigawa M, Verma AK, Simsiman RC, Boutwell RK. Inhibition of mouse skin tumor promotion and of promoter-stimulated epidermal polyamine biosynthesis by alpha-difluoromethylornithine. Cancer Res 1983;43:3732-8.[Abstract]

11 Homma Y, Kakizoe T, Samma S, Oyasu R. Inhibition of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat urinary bladder carcinogenesis by alpha-difluoromethylornithine. Cancer Res 1987;47:6176-9.[Abstract]

12 Love RR, Carbone PP, Verma AK, Gilmore D, Carey P, Tutsch KD, et al. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. J Natl Cancer Inst 1993;85:732-7.[Abstract]

13 Love RR, Jacoby R, Newton MA, Tutsch KD, Simon K, Pomplun M, et al. A randomized, placebo-controlled trial of low-dose {alpha}-difluoromethylornithine in individuals at risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 1998;7:989-92.[Abstract]

14 Meyskens FL Jr, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, et al. Effect of {alpha}-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 1998;90:1212-8.[Abstract/Free Full Text]

15 Heston WD. Prostatic polyamines and polyamine targeting as a new approach to therapy of prostatic cancer. Cancer Surv 1991;11:217-38.[Medline]

16 Heston WD, Kadmon D, Lazan DW, Fair WR. Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of ODC inhibitor {alpha}-difluoromethylornithine. Prostate 1982;3:383-9.[Medline]

17 Loprinzi CL, Love RR, Therneau TM, Verma AK. Inhibition of human skin ornithine decarboxylase activity by oral alpha-difluoromethylonithine. Cancer Therapy Control 1989;1:75-80.

18 Pegg AE. Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 1986;234:249-62.[Medline]

19 Pegg AE. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res 1988;48:759-74.[Abstract]

20 Knapp DW, Richardson RC, Chan TC, Bottoms GD, Widmer WR, DeNicola DB, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-8.[Medline]

Manuscript received January 26, 1999; revised May 27, 1999; accepted June 15, 1999.


This article has been cited by other articles in HighWire Press-hosted journals:


             
Copyright © 1999 Oxford University Press (unless otherwise stated)
Oxford University Press Privacy Policy and Legal Statement